Premium
Development of a recombinant human collagen‐type III based hemostat
Author(s) -
Yang C.,
Hillas P.,
Tang J.,
Balan J.,
Notbohm H.,
Polarek J.
Publication year - 2003
Publication title -
journal of biomedical materials research part b: applied biomaterials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.665
H-Index - 108
eISSN - 1552-4981
pISSN - 1552-4973
DOI - 10.1002/jbm.b.20030
Subject(s) - hemostat , recombinant dna , in vitro , type i collagen , collagen fibril , in vivo , platelet , chemistry , fibril , microbiology and biotechnology , pathology , immunology , biochemistry , biophysics , biology , medicine , surgery , gene
Animal‐tissue‐derived collagen, containing mostly type I collagen with a minor amount of type III collagen, has been widely used in the production of hemostats for many decades, although it has been known for a long time that type III collagen is more likely to induce platelet aggregation in vitro . Because it is hard to purify type III from animal tissue, it has not been possible to correlate this finding with in vivo data. In this report, it is demonstrated that recombinant human collagen III fibrils are more capable of inducing platelet aggregation in vitro than those comprised of bovine collagen I, in agreement with previously published data on tissue‐derived type III collagen. When formed into three‐dimensional matrices, the use of type III collagen results in formulations with better mechanical integrity, larger surface area, and higher hemostatic activity in a rabbit spleen injury model as compared with commercially available hemostats formed from bovine type I collagen. © 2003 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 69B: 18–24, 2004